Selected research
Industry Research
Anti-TIGIT Antibody Industry Research Report 2026
Market perspective
The global Anti-TIGIT Antibody market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Anti-TIGIT Antibody market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Anti-TIGIT Antibody market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Anti-TIGIT Antibody market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Anti-TIGIT Antibody include Arcus, Astellas, BMS, Compugen, Gilead Sciences, Mereo BioPharma, Seattle Genetics, AstraZeneca and BeiGene, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Anti-TIGIT Antibody market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Anti-TIGIT Antibody.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Anti-TIGIT Antibody Market by Company
Arcus
Astellas
BMS
Compugen
Gilead Sciences
Mereo BioPharma
Seattle Genetics
AstraZeneca
BeiGene
Hengrui Medicine
Junshi Biosciences
Roche
Merck
Innovent Biologics
Anti-TIGIT Antibody Segment by Type
Monotherapy
Combination Therapy
Anti-TIGIT Antibody Segment by Application
Cell Carcinoma
Solid Tumor
Anti-TIGIT Antibody Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-TIGIT Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-TIGIT Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-TIGIT Antibody.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Anti-TIGIT Antibody companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Monotherapy
- Combination Therapy
Applications
- Cell Carcinoma
- Solid Tumor
Companies covered
- Arcus
- Astellas
- BMS
- Compugen
- Gilead Sciences
- Mereo BioPharma
- Seattle Genetics
- AstraZeneca
- BeiGene
- Hengrui Medicine
- Junshi Biosciences
- Roche
- Merck
- Innovent Biologics
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Anti-TIGIT Antibody by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Monotherapy
- 2.2.3 Combination Therapy
- 2.3 Anti-TIGIT Antibody by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Cell Carcinoma
- 2.3.3 Solid Tumor
- 2.4 Assumptions and Limitations
3 Anti-TIGIT Antibody Breakdown Data by Type
- 3.1 Global Anti-TIGIT Antibody Historic Market Size by Type (2021-2026)
- 3.2 Global Anti-TIGIT Antibody Forecasted Market Size by Type (2027-2032)
4 Anti-TIGIT Antibody Breakdown Data by Application
- 4.1 Global Anti-TIGIT Antibody Historic Market Size by Application (2021-2026)
- 4.2 Global Anti-TIGIT Antibody Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Anti-TIGIT Antibody Market Perspective (2021-2032)
- 5.2 Global Anti-TIGIT Antibody Growth Trends by Region
- 5.2.1 Global Anti-TIGIT Antibody Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Anti-TIGIT Antibody Historic Market Size by Region (2021-2026)
- 5.2.3 Anti-TIGIT Antibody Forecasted Market Size by Region (2027-2032)
- 5.3 Anti-TIGIT Antibody Market Dynamics
- 5.3.1 Anti-TIGIT Antibody Industry Trends
- 5.3.2 Anti-TIGIT Antibody Market Drivers
- 5.3.3 Anti-TIGIT Antibody Market Challenges
- 5.3.4 Anti-TIGIT Antibody Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Anti-TIGIT Antibody Players by Revenue
- 6.1.1 Global Top Anti-TIGIT Antibody Players by Revenue (2021-2026)
- 6.1.2 Global Anti-TIGIT Antibody Revenue Market Share by Players (2021-2026)
- 6.2 Global Anti-TIGIT Antibody Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Anti-TIGIT Antibody Head Office and Area Served
- 6.4 Global Anti-TIGIT Antibody Players, Product Type & Application
- 6.5 Global Anti-TIGIT Antibody Manufacturers Established Date
- 6.6 Global Anti-TIGIT Antibody Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Anti-TIGIT Antibody Market Size (2021-2032)
- 7.2 North America Anti-TIGIT Antibody Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Anti-TIGIT Antibody Market Size by Country (2021-2026)
- 7.4 North America Anti-TIGIT Antibody Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Anti-TIGIT Antibody Market Size (2021-2032)
- 8.2 Europe Anti-TIGIT Antibody Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Anti-TIGIT Antibody Market Size by Country (2021-2026)
- 8.4 Europe Anti-TIGIT Antibody Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Anti-TIGIT Antibody Market Size (2021-2032)
- 9.2 Asia-Pacific Anti-TIGIT Antibody Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Anti-TIGIT Antibody Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Anti-TIGIT Antibody Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Anti-TIGIT Antibody Market Size (2021-2032)
- 10.2 South America Anti-TIGIT Antibody Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Anti-TIGIT Antibody Market Size by Country (2021-2026)
- 10.4 South America Anti-TIGIT Antibody Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Anti-TIGIT Antibody Market Size (2021-2032)
- 11.2 Middle East & Africa Anti-TIGIT Antibody Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Anti-TIGIT Antibody Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Anti-TIGIT Antibody Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Arcus
- 12.1.1 Arcus Company Information
- 12.1.2 Arcus Business Overview
- 12.1.3 Arcus Revenue in Anti-TIGIT Antibody Business (2021-2026)
- 12.1.4 Arcus Anti-TIGIT Antibody Product Portfolio
- 12.1.5 Arcus Recent Developments
- 12.2 Astellas
- 12.2.1 Astellas Company Information
- 12.2.2 Astellas Business Overview
- 12.2.3 Astellas Revenue in Anti-TIGIT Antibody Business (2021-2026)
- 12.2.4 Astellas Anti-TIGIT Antibody Product Portfolio
- 12.2.5 Astellas Recent Developments
- 12.3 BMS
- 12.3.1 BMS Company Information
- 12.3.2 BMS Business Overview
- 12.3.3 BMS Revenue in Anti-TIGIT Antibody Business (2021-2026)
- 12.3.4 BMS Anti-TIGIT Antibody Product Portfolio
- 12.3.5 BMS Recent Developments
- 12.4 Compugen
- 12.4.1 Compugen Company Information
- 12.4.2 Compugen Business Overview
- 12.4.3 Compugen Revenue in Anti-TIGIT Antibody Business (2021-2026)
- 12.4.4 Compugen Anti-TIGIT Antibody Product Portfolio
- 12.4.5 Compugen Recent Developments
- 12.5 Gilead Sciences
- 12.5.1 Gilead Sciences Company Information
- 12.5.2 Gilead Sciences Business Overview
- 12.5.3 Gilead Sciences Revenue in Anti-TIGIT Antibody Business (2021-2026)
- 12.5.4 Gilead Sciences Anti-TIGIT Antibody Product Portfolio
- 12.5.5 Gilead Sciences Recent Developments
- 12.6 Mereo BioPharma
- 12.6.1 Mereo BioPharma Company Information
- 12.6.2 Mereo BioPharma Business Overview
- 12.6.3 Mereo BioPharma Revenue in Anti-TIGIT Antibody Business (2021-2026)
- 12.6.4 Mereo BioPharma Anti-TIGIT Antibody Product Portfolio
- 12.6.5 Mereo BioPharma Recent Developments
- 12.7 Seattle Genetics
- 12.7.1 Seattle Genetics Company Information
- 12.7.2 Seattle Genetics Business Overview
- 12.7.3 Seattle Genetics Revenue in Anti-TIGIT Antibody Business (2021-2026)
- 12.7.4 Seattle Genetics Anti-TIGIT Antibody Product Portfolio
- 12.7.5 Seattle Genetics Recent Developments
- 12.8 AstraZeneca
- 12.8.1 AstraZeneca Company Information
- 12.8.2 AstraZeneca Business Overview
- 12.8.3 AstraZeneca Revenue in Anti-TIGIT Antibody Business (2021-2026)
- 12.8.4 AstraZeneca Anti-TIGIT Antibody Product Portfolio
- 12.8.5 AstraZeneca Recent Developments
- 12.9 BeiGene
- 12.9.1 BeiGene Company Information
- 12.9.2 BeiGene Business Overview
- 12.9.3 BeiGene Revenue in Anti-TIGIT Antibody Business (2021-2026)
- 12.9.4 BeiGene Anti-TIGIT Antibody Product Portfolio
- 12.9.5 BeiGene Recent Developments
- 12.10 Hengrui Medicine
- 12.10.1 Hengrui Medicine Company Information
- 12.10.2 Hengrui Medicine Business Overview
- 12.10.3 Hengrui Medicine Revenue in Anti-TIGIT Antibody Business (2021-2026)
- 12.10.4 Hengrui Medicine Anti-TIGIT Antibody Product Portfolio
- 12.10.5 Hengrui Medicine Recent Developments
- 12.11 Junshi Biosciences
- 12.11.1 Junshi Biosciences Company Information
- 12.11.2 Junshi Biosciences Business Overview
- 12.11.3 Junshi Biosciences Revenue in Anti-TIGIT Antibody Business (2021-2026)
- 12.11.4 Junshi Biosciences Anti-TIGIT Antibody Product Portfolio
- 12.11.5 Junshi Biosciences Recent Developments
- 12.12 Roche
- 12.12.1 Roche Company Information
- 12.12.2 Roche Business Overview
- 12.12.3 Roche Revenue in Anti-TIGIT Antibody Business (2021-2026)
- 12.12.4 Roche Anti-TIGIT Antibody Product Portfolio
- 12.12.5 Roche Recent Developments
- 12.13 Merck
- 12.13.1 Merck Company Information
- 12.13.2 Merck Business Overview
- 12.13.3 Merck Revenue in Anti-TIGIT Antibody Business (2021-2026)
- 12.13.4 Merck Anti-TIGIT Antibody Product Portfolio
- 12.13.5 Merck Recent Developments
- 12.14 Innovent Biologics
- 12.14.1 Innovent Biologics Company Information
- 12.14.2 Innovent Biologics Business Overview
- 12.14.3 Innovent Biologics Revenue in Anti-TIGIT Antibody Business (2021-2026)
- 12.14.4 Innovent Biologics Anti-TIGIT Antibody Product Portfolio
- 12.14.5 Innovent Biologics Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst